Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcoma

Cancer patients with advanced disease routinely exhaust available clinical regimens and lack actionable genomic medicine results, leaving a large patient population without effective treatments options when their disease inevitably progresses.